Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Moderna Inc (NASDAQ: MRNA) have received a price target of $109 by BMO Capital. These are the details.

MRNA Stock Price: $109 Target By BMO

Moderna's candidate is cool with being kept at warmer temperatures.

Here's Why Moderna's Coronavirus Vaccine Could Outsell Pfizer's

BioNTech SE

Pfizer

Dr. Angela Rasmussen explains why news from Pfizer and Moderna's mRNA vaccine trials is so promising.

What This Virus Expert Thinks About mRNA Vaccine Candidates for COVID-19

It could be great news for the biotech -- and the world.

The Big Thing to Know About Moderna's COVID Vaccine Results

More big news for leaders in the coronavirus vaccine race will be on the way soon.

Near-Term Catalysts to Watch for COVID Vaccine Stocks

Dr. Leo Nissola explains why these two stocks are both likely winners.

Moderna and Pfizer Investors: There's Room For Multiple mRNA Coronavirus Vaccine Winners

Dr. Angela Rasmussen explains how this new class of vaccines can help prevent COVID-19.

Ask A Virologist: How Do mRNA Vaccines Work?

It's going to take more than one successful vaccine to justify these inflated market valuations.

Can the Moderna and BioNTech Bulls Keep Running?

In January, Stéphane Bancel, the chief executive of Moderna, was skimming through the news on his iPad while vacationing with his family in the south of France. A headline stopped his finger: "Health Officials Work to Solve China's Mystery Virus Outbreak," The Wall Street Journal reported on January 6. The Frenchman, who is 48, wrote an email to Dr. Barney Graham, a vaccine researcher at the US National Institutes of Health, asking him what he knew about these pneumonia cases cropping up in central China.

How the sprint for a coronavirus vaccine transformed Moderna into a $39 billion biotech powerhouse that's poised to reshape biotech

Etsy

Zoom Video

Pandemic-related trends have benefited these companies in 2020. But their growth stories are just getting started.

3 High-Growth Companies That More Than Doubled Their Sales Last Quarter

Thinking of investing in the biotech? Beware the coronavirus vaccine hype.

What's the Outlook for Moderna Stock?

Abbott Labs

Novavax

At least two of them could have significant catalysts on the way this month.

3 Top Coronavirus Stocks to Buy in November

AstraZeneca

Johnson & Johnson

The pharmaceutical industry has succeeded in doing its job in manufacturing multiple vaccines for the novel coronavirus, and it's "now in the hands" of government authorities to manage the distribution, Emily Field, head of European pharmaceutical research at Barclays, Emily Field said Friday on CNBC's "Squawk Box Europe." Price Not A Factor: Early indications suggest AstraZeneca plc (NASDAQ: AZN) and Johnson & Johnson's (NYSE: JNJ) vaccine will cost $3 to $5, while pricing for Pfizer Inc. (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) could reach $40 on the high end.

Pharma Sector Did Its Job With COVID-19 Vaccine: Barclays Analyst

Moderna's announcement Monday that its COVID vaccine MRNA-1273 had achieved >90% efficacy was the only way the company could have stolen Pfizer / BioNTech's thunder. The next step is the 2-month safety data review and application for Emergency Use Authorization.

Moderna: I Don't Agree Excellent COVID-19 Vaccine Catalysts Already Baked Into Share Price

Mondelez

Tesla

Workhorse Group

These 7 stocks to buy before 2021 were strong in 2020 and have the characteristics to remain strong next year. Click for more.

7 Hot Stocks to Buy Before 2021 Ushers in Change

In an attempt to “synchronize” COVID-19 vaccine distribution at par with the U.S., the European Union is deliberating the idea of granting  Pfizer Inc (NYSE: PFE)-BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA), a conditional marketing authorization, Bloomberg reports. What Happened: The European authority is holding constant talks with the U.S. Food and Drug Administration to evaluate and assess the vaccine's efficacy, Ursula von der Leyen, President of the European Commission, told Bloomberg.

Pfizer, Moderna COVID-19 Vaccines Could Get Limited EU Approval Before Year-End: Report

BioNtech and Moderna Vaccines May Get Emergency Use Approval In Europe

Dr. Jeremy Brown knows a lot about pandemics. Here's what he thinks about the exciting trial data coming from Pfizer and BioNTech.

Doctor and Pandemic Expert Shares What Investors Need To Know About Coronavirus Vaccines

FDA approval for emergency usage is the first step to getting the COVID-19 vaccine to the public.

Pfizer, Moderna to file FDA COVID-19 vaccine emergency usage as soon as Friday

Health and Human Services Secretary Alex Azar said Thursday that Pfizer is expected to file an application to the FDA for emergency use of its coronavirus vaccine on Friday, with Moderna soon to follow.

HHS Secretary Azar says Pfizer is expected to file FDA application for coronavirus vaccine Friday with Moderna soon to follow

Bio-Rad Laboratories

Insulet

Health Care Select Sector SPDR Fund

These are the healthcare stocks with the best value, fastest growth, and most momentum for December 2020.

Top Healthcare Stocks for December 2020

Gilead Sciences

Eli Lilly

Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.

What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?

GlaxoSmithKline

Sanofi

Dr. Angela Rasmussen explains why news from mRNA vaccine trials is so promising and shares tips for investors thinking about buying stocks like Pfizer and Moderna.

A Virologist Explains: mRNA Coronavirus Vaccines And What Investors Should Know

If all goes well, by mid-2021 people in the US may have two — or more — safe, highly effective coronavirus vaccines to use. On Wednesday, Pfizer announced it had completed its final coronavirus vaccine trial, and shown its 2-shot course to be 95% effective at preventing infections in the more than 40,000 people who tested it out around the world. Earlier in the week, Moderna also announced its own coronavirus vaccine trial was nearing its end, with a very similar 94.5% efficacy rate.

Moderna's coronavirus vaccine doesn't need to be as icy cold as Pfizer's, and that could make it easier to distribute

Moderna, Inc. (MRNA) CEO Stéphane Bancel Presents at Jefferies 2020 Virtual London Healthcare Conference (Transcript)

News for Moderna Stock (MRNA)